Research Topics
| Jame AbrahamSummaryAffiliation: West Virginia University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imagingJame Abraham
Department of Medicine, Section of Hematology and Oncology, Johns Hopkins University, Baltimore, MD, USA
Clin Breast Cancer 8:88-91. 2008..The purpose of this study was to examine the effect of adjuvant chemotherapy on normal-appearing white matter in women with breast cancer...
Initial clinical test of a breast-PET scannerRaymond R Raylman
Department of Radiology Hematology Oncology, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA
J Med Imaging Radiat Oncol 55:58-64. 2011..Specifically, the main task of this study is to determine whether the new system can successfully be used to produce images of known breast cancer and compare them to those acquired by standard techniques...
Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinomaRamin Altaha
Section of Hematology/Oncology, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia, USA
Cancer 103:442-3. 2005- Actinic keratosis and capecitabine therapyGerald M Higa
Department of Medicine, Section of Hematology Oncology, West Virginia University, Morgantown, USA
J Oncol Pharm Pract 11:151-3. 2005..During treatment, an apparent toxic skin reaction occurs before dermal quiescence ensues. We report a case of a typical flare of AK in a woman treated with capecitabine for advanced breast cancer... - Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in ratsGregory W Konat
Department of Neurobiology and Anatomy, West Virginia University School of Medicine, 4052 HSCN, P O Box 9128, Morgantown, WV 26506 9128, USA
Metab Brain Dis 23:325-33. 2008..Moreover, the results strongly indicate that the damaging effect is mediated by oxidative stress, as memory dysfunction is preventable by the co-administration of NAC... - Thymic hyperplasia after adjuvant chemotherapy in breast cancerAasim S Sehbai
Section of Hematology Oncology, West Virginia University, Morgantown, WV 26506 9162, USA
J Thorac Imaging 21:43-6. 2006..Awareness of this unusual side effect in patients treated with chemotherapy may prevent unnecessary investigation and surgical intervention... - Paraneoplastic neurologic syndrome associated with occult breast cancer: a case report and review of literatureRamin Altaha
West Virginia University Hospital, Section of Hematology Oncology, Mary Babb Randolph Cancer Center, Morgantown, West Virginia 26506 9162, USA
Breast J 9:417-9. 2003..Only 29% of patients responded to chemotherapy with improvement in neurologic deficits. The role of systemic treatment in the progression of neurologic impairment is unclear... - Lapatinib in the treatment of breast cancerGerald M Higa
Mary Babb Randolph Cancer Center, School of Pharmacy, West Virginia University, Morgantown, WV 26506, USA
Expert Rev Anticancer Ther 7:1183-92. 2007..Recently, lapatinib, a small molecule dual inhibitor of both HER2 and EGF receptors, has been developed to expand the options for treating HER-positive breast cancer... - CNS metastasis in primary breast cancerManish Sharma
Mary Babb Randolph Cancer Center Clinic, West Virginia University, PO Box 9162, Morgantown, WV 26506 9162, USA
Expert Rev Anticancer Ther 7:1561-6. 2007..This review focuses on the treatment options available for both brain and leptomeningeal metastasis from breast cancer, including some investigational therapies that may be of importance in patient management in the near future... - Anemia and neutropenia associated with copper deficiency of unclear etiologyWilliam Harless
Division of Hematology and Oncology, West Virginia University, Morgantown, 26506, USA
Am J Hematol 81:546-9. 2006.... - Perioperative management of a patient with May-Hegglin anomaly requiring craniotomyAasim S Sehbai
Section of Hematology Oncology, West Virginia University School of Medicine, Morgantown, West Virginia 26505, USA
Am J Hematol 79:303-8. 2005..With this approach, the use of platelet concentrates could be avoided. We discuss the role of DDAVP in MHA and related platelet disorders and review the current literature... - Prognostic significance of the "surprise" question in cancer patientsAlvin H Moss
West Virginia University, Morgantown, West Virginia 26506, USA
J Palliat Med 13:837-40. 2010..It has not been previously studied in patients with cancer... - Role of MRI in screening, diagnosis and management of breast cancerAnil Kumar Swayampakula
Department of Community Medicine, School of Medicine, West Virginia University, Morgantown, WV 26506, USA
Expert Rev Anticancer Ther 8:811-7. 2008..This article focuses on the role of MRI in diagnosis, screening and management of breast cancer, and reviews the current indications for breast MRI... - Managing early breast cancer: prognostic features guide choice of therapyHamid R Mirshahidi
Mary Babb Randolph Cancer Center, West Virginia University, Morgantown 26505, USA
Postgrad Med 116:23-6, 32-4. 2004..Here, the authors present the current considerations and treatment guidelines for early-stage breast cancer... - High-dose therapy and autologous stem cell transplantation in relapsed and refractory Hodgkin's disease: outcome based on a prognostic modelMuzaffar H Qazilbash
Blood and Marrow Transplantation Program, West Virginia University, Morgantown, W VA, USA
Acta Haematol 110:173-8. 2003..The use of a prognostic model appears useful for predicting the outcome of HDT and ASCT for HD patients, and may play an important role in choosing the appropriate therapy for these patients... - Role of tumor markers and circulating tumors cells in the management of breast cancerAyman Saad
Department of Internal Medicine School of Medicine West Virginia University, WV 26506 9162, USA
Oncology (Williston Park) 22:726-31; discussion 734, 739, 743-4. 2008..This article will discuss the current data on these markers, with special emphasis on the CTC test. The potential clinical utility of these markers will also be discussed... - Correlation among [18F]fluorodeoxyglucose positron emission tomography/computed tomography, cancer antigen 27.29, and circulating tumor cell testing in metastatic breast cancerAyman Saad
Neoplastic Diseases and Related Disorders, Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
Clin Breast Cancer 8:357-61. 2008..Recently, circulating tumor cell testing (CTC) has been used in this context. It is not known if 1 of the 3 tests can be a surrogate for another... - Cognitive impairment with significant brain parenchymal volume loss following standard adjuvant chemotherapy in a patient with breast cancerAnil Kumar Swayampakula
Department of Community Medicine, Mary Babb Randolph Cancer Center, West Virginia University School of Medicine, Morgantown, WV 26506, USA
Clin Adv Hematol Oncol 5:985-7; discussion 987-8. 2007 - Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patientsHui Huang
Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Cancer 113:2020-8. 2008..A long-term follow-up was conducted of 18 patients with a diagnosis of pheochromocytoma/paraganglioma treated with a combination of cyclophosphamide, vincristine, and dacarbazine (CVD)... - Ixabepilone: a new microtubule-targeting agent for breast cancerGerald M Higa
Mary Babb Randolph Cancer Center, School of Pharmacy, West Virginia University, Morgantown, WV 26506, USA
Expert Rev Anticancer Ther 8:671-81. 2008.... - Population-based molecular prognosis of breast cancer by transcriptional profilingYan Ma
Mary Babb Randolph Cancer Center, Department of Statistics, Division of Hematology, West Virginia University, Morgantown, WV 26506 9300, USA
Clin Cancer Res 13:2014-22. 2007..The purpose of this study is to predict breast cancer recurrence and metastases and to identify gene signatures indicative of clinicopathologic characteristics using gene expression patterns derived from cDNA microarray... - Epidermal growth factor receptor as a target for cancer therapyRamin Altaha
Expert Rev Anticancer Ther 7:1-3. 2007 - Breast and ovarian cancer genetics and preventionRamin Altaha
Section of Hematology/Oncology, Mary Babb Randolph Cancer Center, West Virginia University Hospitals, Morgantown, USA
W V Med J 99:187-91. 2003..Likewise, genetic counseling prior to testing is important, considering the major impact of the test results on an individual's life... - Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five daysJame Abraham
Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, USA
J Clin Oncol 21:1866-73. 2003..Neutropenia was dose limiting, but higher doses were tolerated by a large fraction of patients with filgrastim support. Peripheral neuropathy was mild, even after multiple cycles of therapy, and was not dose limiting... - Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastasesBradford J Wood
Special Procedures, Department of Diagnostic Radiology, Clinical Center, National Institutes of Health Clinical Center, Bethesda, Maryland, USA
Cancer 97:554-60. 2003.... - Epothilones: a novel class of non-taxane microtubule-stabilizing agentsRamin Altaha
West Virginia University, Mary Babb Randolph Cancer Center, Robert C. Byrd Health Sciences Center, Morgantown, West Virginia, 26506, USA
Curr Pharm Des 8:1707-12. 2002..This article will review some basic aspects of epothilone chemistry and biology, and pre-clinical and preliminary clinical experience with epothilone B and its analog, BMS 247550... - A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonistJame Abraham
Medicine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Cancer 94:2333-43. 2002..The superiority of this combination over single-agent mitotane is uncertain. The side effects of mitotane made treatment difficult. More effective Pgp antagonists are needed...